Zeena Salman - Concepedia

Author

Zeena Salman

Dana-Farber Cancer Institute ORCID

Also Known As

Fatema AlQassab, Z. Salman, Z.K. Salman, Zahra Amer Salman, Zakeya Salman, Zeena Salman, Zinah Salman

124

Publications

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Pharmacyclics (United States)Memorial Sloan Kettering Cancer Center AbbVie (United States)Sarah Cannon

About

Zeena Salman is an author at Dana-Farber Cancer Institute specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	220
2	Health Sciences	2	2	57
3	Public Health	1	1	61
4	Epidemiology	1	1	61
5	Global Health	1	1	61

Zeena Salman

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia Steven P. Treon, Christina Tripsas, Kirsten Meid, New England Journal of Medicine	2015	913
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia Meletios Α. Dimopoulos, Alessandra Tedeschi, Judith Trotman, New England Journal of Medicine	2018	342
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, Cancer Discovery	2024	231
652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) Kathryn C. Arbour, Salman R. Punekar, Ignacio Garrido‐Laguna, Annals of Oncology Tumor BiologyMedicinePharmacologyPathologyPreliminary Clinical Activity	2023	102
High Rate of Obesity-Associated Hypertension among Primary Schoolchildren in Sudan Zeena Salman, Gregory D. Kirk, Mark D. DeBoer International Journal of Hypertension ObesityChildhood ObesityHypertensionCardiovascular EpidemiologyCardiovascular Disease	2010	61
Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study Jennifer R. Brown, Jacqueline C. Barrientos, Paul M. Barr, Blood	2013	46
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results Paul G. Richardson, William Bensinger, Carol Ann Huff, British Journal of Haematology	2018	36
A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. Anthony W. Tolcher, Benedito A. Carneiro, Afshin Dowlati, Journal of Clinical Oncology Cancer ManagementImmunologyPathologyPharmacotherapyMetronomic Chemotherapy	2021	32
Trends in childhood cancer: Incidence and survival analysis over 45 years of SEER data Iyad Sultan, Ahmad Samir Alfaar, Yaseen Sultan, PLoS ONE	2025	29
T <sub>1</sub> cortical hypointensities and their association with cognitive disability in multiple sclerosis Francesca Bagnato, Zeena Salman, Robert L Kane, Multiple Sclerosis Journal	2010	28

Page 1